SCHEDULE: NEA Group's Senti Biosciences Stake Dips to 12.1%

New Enterprise Associates and affiliated entities report a decrease in their beneficial ownership of Senti Biosciences, Inc. common stock to 12.1% due to an increase in outstanding shares.

Summary

• New Enterprise Associates 15, L.P. (NEA 15) and its affiliated entities, including NEA Partners 15, L.P., NEA 15 GP, LLC, and individual managers (Forest Baskett, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, and Scott D. Sandell), collectively referred to as the Reporting Persons, filed an Amendment No. 3 to their Schedule 13D.
• The amendment reports a decrease in the beneficial ownership of Senti Biosciences, Inc. common stock by more than 1%.
• The decrease is attributed to an increase in the total number of Senti Biosciences' common stock outstanding, not a sale of shares by the Reporting Persons.
• As of March 27, 2026, the Reporting Persons beneficially own 3,775,615 shares of Senti Biosciences common stock.
• This represents 12.1% of the outstanding common stock, calculated based on 31,144,497 shares reported by Senti Biosciences as outstanding on March 19, 2026.
• NEA 15 initially acquired the shares for investment purposes and may acquire or dispose of additional shares based on market conditions and evaluation of the Issuer's business and prospects.
• No transactions in Senti Biosciences shares were effected by the Reporting Persons during the last 60 days prior to the filing date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a factual reporting of a change in beneficial ownership percentage due to an increase in outstanding shares, rather than a strategic move by the reporting entity.

Negatives

• The percentage of beneficial ownership held by the Reporting Persons decreased by more than 1%, indicating dilution for existing shareholders due to an increase in the total number of outstanding shares of Senti Biosciences, Inc.

Future Outlook

The Reporting Persons may dispose of or acquire additional shares of Senti Biosciences, Inc. depending on market conditions, their continuing evaluation of the business and prospects of the Issuer, and other factors. There are no present plans for extraordinary corporate transactions, changes in management or board, material changes in capitalization or dividend policy, or other material changes to the Issuer's business or corporate structure.

Industry Context

StockSavvy.ai notes that this filing is a routine update on beneficial ownership by a venture capital firm in a biotechnology company. While not directly indicative of broader industry trends, changes in significant investor stakes can sometimes signal shifts in investor confidence or strategic positioning within the biotech sector, particularly for early-stage or growth-oriented companies like Senti Biosciences.

Stakeholder Impact

• Shareholders: The increase in outstanding shares, which led to the decrease in percentage ownership for the Reporting Persons, implies dilution for existing shareholders if they did not participate in the share issuance. However, the filing does not provide details on the nature of the share increase.

Next Steps

• Reporting Persons may acquire or dispose of additional shares of Senti Biosciences, Inc. in the future.

Key Dates

Recommendation

This filing is a routine disclosure of a change in beneficial ownership percentage due to an increase in the issuer's outstanding shares, not a change in the reporting entity's investment thesis or a significant operational update. It does not provide sufficient new information to warrant a change in investment recommendation based solely on its content. Investors should consider Senti Biosciences' broader financial performance and strategic developments.

Keywords

Senti Biosciences, NEA, New Enterprise Associates, Schedule 13D, Beneficial Ownership, Common Stock, Equity Investment, Biotechnology, Dilution